Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis-Reference-Cited by-同舟云学术

Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis

Published:2018-03-22 Issue:1 Volume:20 Page:
ISSN:1478-6362
Container-title:Arthritis Research & Therapy
language:en
Short-container-title:Arthritis Res Ther

Author:

Weigold Florian,Günther Jeannine,Pfeiffenberger Moritz,Cabral-Marques Otavio,Siegert Elise,Dragun Duska,Philippe Aurélie,Regensburger Ann-Katrin,Recke Andreas,Yu Xinhua,Petersen Frank,Catar Rusan,Biesen Robert,Hiepe Falk,Burmester Gerd R.,Heidecke Harald,Riemekasten Gabriela

Funder

Deutsche Forschungsgemeinschaft

Mirjam Lichy foundation

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s13075-018-1545-8.pdf

Reference34 articles.

1. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69:1809–15.

2. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89:207–15.

3. Murdoch C. CXCR4: chemokine receptor extraordinaire. Immunol Rev. 2000;177:175–84.

4. Lacotte S, Brun S, Muller S, Dumortier H. CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci. 2009;1173:310–7.